Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)

NCT00975130 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3366

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

BIOLOGICAL: SC golimumab
BIOLOGICAL: IV golimumab

Sponsor

Merck Sharp & Dohme LLC